- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03976180
High-flow Oxygen for Vaso-occlusive Pain Crisis (OSONE)
A Multicentre, Prospective, Randomized, Multi-arm, Multi-stage Clinical Trial of High-flow Oxygen for Vaso-occlusive Pain Crisis in Adult Patients With Sickle Cell Disease;
Sickle cell disease (SCD) is characterized by recurrent vaso-occlusive pain crisis (VOC), which may evolve to acute chest syndrome (ACS), the most common cause of death among adult patients with SCD. Currently, there is no safe and effective treatment to abort VOC or prevent secondary ACS. Management of VOC mostly involve a symptomatic approach including hydration, analgesics, transfusion, and incentive spirometry, which was investigated in a very limited number of patients (<30).
The polymerisation of HbS is one major feature in the pathogenesis of vaso-occlusion. Among factors determining the rate and extent of HbS polymer formation, the hypoxic stimulus is one of the most potent and readily alterable. Current guidelines recommend oxygen therapy in patients with VOC in order to maintain a target oxygen saturation of 95%. Low-flow nasal oxygen (LFNO) is routinely used to achieve this normoxia approach, particularly in patients at risk of secondary ACS because they may experience acute desaturation. In contrast, various case series suggest a potential beneficial role of intensified oxygen therapy targeting hyperoxia for the management of VOC, particularly with the use of hyperbaric oxygen, but the latter is difficult to implement in routine clinical practice.
A recent high-flow nasal oxygen (HFNO) technology allows the delivery of humidified gas at high fraction of inspired oxygen (FiO2) through nasal cannula. The FiO2 can be adjusted up to 100% (allowing hyperoxia that may reverse sickling) and the flow can be increased up to 60 L/min (which generates positive airway pressure and dead space flushing, that may prevent evolution of VOC towards ACS by alleviating atelectasis and opioid-induced hypercapnia). In patients with acute respiratory failure, HFNO has been shown to improve patient's comfort, oxygenation, and survival as compared to standard oxygen or non-invasive ventilation.
The aim of the present study is to test the efficacy and safety of HFNO for the management of VOC and prevention of secondary ACS. The investigators will use a multi-arm multi-stage (MAMS) design to achieve these goals. HFNO will be delivered through AIRVO 2 (Fisher and Paykel Healthcare, New Zealand), a device that incorporates a turbine allowing its use in hospital wards.
Study Overview
Status
Conditions
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Armand Mekontso, MD, PhD
- Phone Number: +33 (1) 49 81 23 94
- Email: armand.dessap@aphp.fr
Study Locations
-
-
-
Créteil, France, 94000
- Recruiting
- Henri Mondor
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥ 18 years;
- Patient with major sickle cell disease syndrome (SS, SC, Sβ0 or Sβ+);
- VOC as defined by acute pain or tenderness, affecting at least one part of the body, including limbs, ribs, sternum, head (skull), spine, and/or pelvis, that requires opioids and is not attributable to other causes;
- Intermediate-to-high risk for secondary ACS derived from the PRESEV score (Bartolucci et al, EBioMedicine 2016) as follows: a reticulocyte count >216 G/L OR at least two of the followings : i) spine and/or pelvis CPS >1; ii) leucocyte count >11G/L; iii) hemoglobin ≤ 9 g/dL;
- Informed consent;
- Patient affiliated to social security
Exclusion Criteria:
- The presence at inclusion of a primary ACS. Primary ACS is defined by the combination at time of inclusion of a clinical sign [chest pain or auscultatory abnormality (crepitants and/or bronchial breathing)] with a new pulmonary infiltrate (on chest film, thoracic scan, or lung ultrasound);
- VOC lasting longer than 72 hours at time of inclusion;
- Known pregnancy or current lactation; Women of child bearing potential will be tested for pregnancy before inclusion;
- Chronic transfusion program;
- Known cerebral vasculopathy or past medical history of stroke;
- Known ischemic heart disease or typical chest angina;
- Patient who is currently enrolled in other investigational drug study;
- Previous participation in this study.
- Known legal incapacity,
- Prisoners or subjects who are involuntarily incarcerated
- Anatomical factors precluding placement of a nasal cannula
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: standard low-flow oxygen
In the control group, standard low-flow oxygen will be delivered via nasal prongs (LFNO), up to hospital discharge or secondary ACS onset, in order to achieve normoxia (target pulse oxymetry saturation of 95%).
This strategy is in accordance with current recommendations and usual care;
|
In the control group, standard low-flow oxygen will be delivered via nasal prongs (LFNO), up to hospital discharge or secondary ACS onset, in order to achieve normoxia (target pulse oxymetry saturation of 95%).
This strategy is in accordance with current recommendations and usual care
Other Names:
|
Experimental: HFNO with low FiO2 (21%-30%)
HFNO with low FiO2 (21%-30%) targeting normoxia: to test the effect of improved pulmonary function;
|
HFNO with low FiO2 (21%-30%) targeting normoxia: to test the effect of improved pulmonary function
Other Names:
|
Experimental: HFNO with intermediate FiO2 (50%)
HFNO with intermediate FiO2 (50%): to test the combined effect of improved pulmonary function and moderate hyperoxia; in this group, FiO2 will be set at 50% during the first 24 hours of intervention to target moderate hyperoxia, then reduced to 21-30% during the following 48 hours to target normoxia
|
In this group, FiO2 will be set at 50% during the first 24 hours of intervention to target moderate hyperoxia, then reduced to 21-3025% during the following 48 hours to target normoxia
Other Names:
|
Experimental: HFNO with high FiO2 (100%)
HFNO with high FiO2 (100%): to test the combined effect of improved pulmonary function and intense hyperoxia; in this group, FiO2 will be set at 100% during the first 24 hours of intervention to target intense hyperoxia, then reduced to 21-30% during the following 48 hours to target normoxia
|
In this group, FiO2 will be set at 100% during the first 24 hours of intervention to target intense hyperoxia, then reduced to 21-3025% during the following 48 hours to target normoxia
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of cardiac and neurologic related events (Pilot Stage)
Time Frame: At the end end of the "pilot stage" and up to 28 days
|
This endpoint will be assessed at the end of the "pilot stage" and throughout the entire study for cumulative safety information.
Research arms will only continue to recruitment in the next stage if they have been shown to be both safe (<5 cardiac or neurologic related events, in the arm during the pilot phase as defined by one of the following: acute coronary syndrome, acute ischemic stroke, or seizure) and feasible (<8 definitive discontinuations before day-2 due to patient's intolerance), although patient data from all patients and all stages will be included in the final analyses.
|
At the end end of the "pilot stage" and up to 28 days
|
Rate of vaso-occlusive pain crisis (VOC) resolution without complication (Activity stage)
Time Frame: Day 5
|
VOC will be considered terminated when at least 3 of the following 4 criteria are met at two consecutive assessments: i) absence of fever for 8 hours; ii) absence of pain progression and no requirement of intravenous infusion of opioid analgesics for the last 8 hours; iii) the patient is able to walk or move without pain; iv) absence of spontaneous pain with a CPS (categorical pain score) of 1 or less
|
Day 5
|
Rate of secondary acute chest syndrome (ACS)(Efficacy Stage)
Time Frame: Day 14
|
Defined as the proportion of patients with secondary ACS during the 14 days following randomization.
Secondary ACS is defined as the combination after randomization of a clinical sign [chest pain or auscultatory abnormality (crepitants and/or bronchial breathing)] with a new pulmonary infiltrate (on chest film, thoracic scan, or lung ultrasound).
|
Day 14
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Volume of transfused red blood cells and volume of exsanguinated blood
Time Frame: Between day-1 (randomization) and day-14
|
Between day-1 (randomization) and day-14
|
|
Pain intensity evaluated by categorical pain score
Time Frame: Between day-1 (randomization) and day-14
|
Pain intensity evaluated with categorical pain score (CPS).
Patients will grade their pain (range 0-3 points, with 0, no pain; 1, mild pain, unaffected by mobilization; 2, moderate pain, increased by mobilization; 3, severe pain with disability) in seven body sites (all four limbs, ribs and sternum, head, and spine and pelvis)
|
Between day-1 (randomization) and day-14
|
Pain intensity evaluated by visual analogue scale
Time Frame: Between day-1 (randomization) and day-14
|
Pain intensity evaluated with the visual analogue pain scale (VAS) .It is presented as a 10 cm horizontal line on which the patient's pain intensity is represented by a point between the extremes of "no pain at all" and "worst pain imaginable."
|
Between day-1 (randomization) and day-14
|
VOC duration
Time Frame: Day-14
|
Day-14
|
|
VOC-free days
Time Frame: Day-14
|
Day-14
|
|
Reticulocyte count
Time Frame: Day-2 and Day-5
|
Day-2 and Day-5
|
|
Arterial blood gas
Time Frame: Up to 24 hours
|
Arterial blood gas assessed at least once during the first 24 hours of treatment (if available)
|
Up to 24 hours
|
Cumulative doses of intravenous and subcutaneous opioids
Time Frame: Between day-1 (randomization) and day-14
|
Between day-1 (randomization) and day-14
|
|
Number of complicated VOC
Time Frame: Day-14
|
A complicated VOC is defined as the occurrence of at least one of the following events between randomization and day-14: transfusion, exchange transfusion, mechanical ventilation, shock (catecholamine infusion), intensive care admission or death.
|
Day-14
|
Duration of hospital stay
Time Frame: Day-28
|
Defined as the time from randomization to hospital discharge; patients still hospitalized at day-28 will be attributed a hospital stay of 28 days)
|
Day-28
|
Number of re-hospitalizations or emergency department consultations for VOC or ACS
Time Frame: Up to 28 days
|
Up to 28 days
|
|
Number of death (Mortality)
Time Frame: Day-28
|
Day-28
|
Collaborators and Investigators
Investigators
- Study Chair: Armand Mekontso, Assistance Publique - Hôpitaux de Paris
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- P180303J
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sickle Cell Disease
-
Klein Buendel, Inc.National Institute on Minority Health and Health Disparities (NIMHD); Hilton...CompletedSickle Cell Disease | Sickle Cell Anemia in Children | Sickle Cell Thalassemia | Sickle Cell SC DiseaseUnited States
-
Nova Laboratories LimitedCompletedSickle Cell Disease | Sickle Cell Hemoglobin C | Sickle Cell-beta-thalassemia | Sickle-Cell; Hemoglobin Disease, ThalassemiaUnited Kingdom, Jamaica
-
SangartCompletedSickle Cell Disease | Anemia, Sickle Cell | Sickle Cell Anemia | Hemoglobin SC Disease | Sickle Cell Disorders | Sickle Cell Hemoglobin C DiseaseUnited Kingdom, France, Jamaica, Lebanon
-
SangartWithdrawnSickle Cell Disease | Anemia, Sickle Cell | Sickle Cell Anemia | Hemoglobin SC Disease | Sickle Cell Disorders | Sickle Cell Hemoglobin C DiseaseFrance, United Kingdom, Netherlands, Turkey, Bahrain, Belgium, Brazil, Lebanon, Qatar
-
University of British ColumbiaCompletedSickle Cell Disease | Beta-Thalassemia | Sickle Cell Trait | Sickle Cell-Beta Thalassemia | Sickle Cell-SS DiseaseCanada, Nepal
-
Sidney Kimmel Cancer Center at Thomas Jefferson...National Heart, Lung, and Blood Institute (NHLBI)TerminatedSickle Cell Anemia | Sickle Cell-hemoglobin C Disease | Sickle Cell-β0-thalassemiaUnited States
-
University of RegensburgRecruitingSickle Cell Disease | Sickle Cell Anemia | Sickle Cell Disorders | HbS Disease | Hemoglobin S Disease | Sickling Disorder Due to Hemoglobin SGermany, Austria
-
Centre Hospitalier Intercommunal CreteilRecruitingSickle-Cell Disease Nos With CrisisFrance
-
HemaQuest Pharmaceuticals Inc.TerminatedSickle Cell Disease | Sickle Cell Anemia | Sickle Cell Disorders | Hemoglobin S Disease | Sickling Disorder Due to Hemoglobin SUnited States, Lebanon, Egypt, Canada, Jamaica
-
HemaQuest Pharmaceuticals Inc.CompletedSickle Cell Disease | Sickle Cell Anemia | Sickle Cell Disorders | Hemoglobin S Disease | Sickling Disorder Due to Hemoglobin SUnited States, Lebanon, Canada, Egypt, Jamaica
Clinical Trials on Stadard low-flow oxygen
-
Johns Hopkins UniversityThrasher Research Fund; University of North Carolina Project- Lilongwe, MalawiNot yet recruiting
-
M.D. Anderson Cancer CenterCompleted
-
Yonsei UniversityCompletedObstructive Sleep ApneaKorea, Republic of
-
Seoul National University HospitalUnknownPostoperative Respiratory ComplicationKorea, Republic of
-
Navy General Hospital, BeijingCompletedFetal Distress | Oxygen Inhalation Therapy | Second Stage of LabourChina
-
Assistance Publique - Hôpitaux de ParisInstitut National de la Santé Et de la Recherche Médicale, FranceCompleted
-
Aga Khan University Hospital, PakistanUnknownApneic Oxygenation
-
University of ZurichNational Center of Cardiology and Internal Medicine named after academician...CompletedChronic Obstructive Pulmonary DiseaseKyrgyzstan
-
Mayo ClinicCompletedStroke, AcuteUnited States